title: Q: Should we use pharmacogenetic testing when prescribing warfarin?
authors.affiliation: Center for Personalized Healthcare, Cleveland Clinic, Cleveland, OH 44195, USA.
authors.forename: Mary
authors.initials: M
authors.lastname: Rouse
authors.forename: Cari
authors.initials: C
authors.lastname: Cristiani
authors.forename: Kathryn A
authors.initials: KA
authors.lastname: Teng
mesh_terms: D000925:Anticoagulants / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000494:pharmacology; D001189:Aryl Hydrocarbon Hydroxylases / Q000235:genetics; D065729:Cytochrome P-450 CYP2C9; D016903:Drug Monitoring; D005820:Genetic Testing; D006801:Humans; D010597:Pharmacogenetics; D017410:Practice Guidelines as Topic; D064417:Vitamin K Epoxide Reductases / Q000235:genetics; D014859:Warfarin / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000494:pharmacology
chemical_list: D000925:Anticoagulants; D014859:Warfarin; C450260:CYP2C9 protein, human; D065729:Cytochrome P-450 CYP2C9; D001189:Aryl Hydrocarbon Hydroxylases; C578523:VKORC1 protein, human; D064417:Vitamin K Epoxide Reductases